Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

por Reifsnider, Odette S, Kansal, Anuraag R, Gandhi, Pranav K, Cragin, Lael, Brand, Sarah B, Pfarr, Egon, Fahrbach, Kyle, Ustyugova, Anastasia
Publicado 2021

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia

por Kansal, Anuraag R., Reifsnider, Odette S., Brand, Sarah B., Hawkins, Neil, Coughlan, Anna, Li, Shujun, Cragin, Lael, Paramore, Clark, Dietz, Andrew C., Caro, J. Jaime
Publicado 2021

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure

por Reifsnider, Odette S., Kansal, Anuraag R., Franke, Jennifer, Lee, Joseph, George, Jyothis T., Brueckmann, Martina, Kaspers, Stefan, Brand, Sarah B., Ustyugova, Anastasia, Linden, Stephan, Stargardter, Matthew, Hau, Nikco
Publicado 2020